Neuroprotective Effects of Pre-Treament with l-Carnitine and Acetyl-l-Carnitine on Ischemic Injury In Vivo and In Vitro by Zhang, Rui et al.
Int. J. Mol. Sci. 2012, 13, 2078-2090; doi:10.3390/ijms13022078 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
Neuroprotective Effects of Pre-Treament with L-Carnitine and 
Acetyl-L-Carnitine on Ischemic Injury In Vivo and In Vitro 
Rui Zhang 
1, Hong Zhang 
2, Zhongxia Zhang 
1, Tao Wang 
3, Jingya Niu 
1, Dongsheng Cui 
1 and 
Shunjiang Xu 
1,* 
1  Central Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang 050031, China; 
E-Mails: doudouzr511@yahoo.cn (R.Z.); smallrainn@gmail.com (Z.Z.); jyniu163@163.com (J.N.);  
dongshengcui@sina.com (D.C.) 
2  Handan City Hospital for Infectious Diseases, Handan 056002, China;  
E-Mail: zhanghong_handan@sina.com 
3  Handan county Hospital, Handan 056002, China; E-Mail: wangtao9979@126.com 
*  Author to whom correspondence should be addressed; E-Mail: sjxu66@hotmail.com; 
Tel: +86-311-8591-7257; Fax: +86-311-8591-7290. 
Received: 2 November 2011; in revised form: 8 January 2012 / Accepted: 7 February 2012 / 
Published: 15 February 2012 
 
Abstract: The therapeutic effect of stroke is hampered by the lack of neuroprotective drugs 
against ischemic insults beyond the acute phase. Carnitine plays important roles in 
mitochondrial metabolism and in modulating the ratio of coenzyme A (CoA)/acyl-CoA. 
Here, we investigate the neuroprotective effects of L-carnitine (LC) and Acetyl-L-carnitine 
(ALC) pre-treatment on ischemic insults under the same experimental conditions. We used 
a transient middle cerebral artery occlusion (MCAO) model to evaluate the protective roles 
of LC and ALC in acute focal cerebral ischemia in vivo and to understand the possible 
mechanisms using model of PC12 cell cultures in vitro. Results showed that ALC, but not 
LC, decreased infarction size in SD rats after MCAO in vivo. However, both LC and ALC 
pretreatment reduced oxygen-glucose deprivation (OGD)-induced cell injury and decreased 
OGD-induced cell apoptosis and death in vitro; at the same time, both of them increased 
the activities of super oxide dismutase (SOD) and ATPase, and decreased the concentration 
of malondialdehyde (MDA) in vitro. Thus, our findings suggested that LC and ALC   
pre-treatment are highly effective in the prevention of neuronal cell against ischemic injury 
in vitro, however, only ALC has the protective effect on neuronal cell injury after   
ischemia in vivo. 
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1. Introduction 
Ischemic stroke is considered as one of the leading causes of death and disability all over the  
globe [1]. A considerable proportion of strokes result from thromboembolic occlusion of major 
intracerebral vessels including the middle cerebral artery (MCA). Following focal cerebral ischemia, 
neuronal cell death is caused by both the core necrosis and the penumbra apoptosis within minutes to 
days [2–4]. The neuronal death after ischemia is closely linked to the essential role of mitochondrial 
metabolism. Cerebral ischemia leads to mitochondrial dysfunction due to lack of oxygen, leaving the 
glycolytic metabolism as a main pathway for energy production. Inhibition of mitochondrial 
respiratory chain triggers generation of lactate and hydrogen ions and dramatically reduces ATP 
generation leading to a dysregulation of cellular ion metabolism with subsequent intracellular calcium 
accumulation [5]. Although many efforts were made to develop novel drugs in order to rescue neurons 
from delayed neuronal death (DND) in the penumbral region, few drugs have shown efficacy currently 
in stroke patients [6]. Therefore we sought to elucidate the therapeutic benefits of prophylactic drugs to 
help reduce the severity of the stroke. 
Figure 1. Chemical structure of L-carnitine (LC) (a) and Acetyl-L-carnitine (ALC) (b). 
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L-carnitine (4-N-trimethylamino-3-hydroxybutyric acid, LC) (Figure 1a) is an essential co-factor in 
the metabolism of lipids and consequently in the production of cellular energy [7]. This molecule plays 
important physiological roles in the β-oxidation of fatty acids by facilitating the transport of long-chain 
fatty acids across the mitochondrial inner membrane as acylcarnitine esters and the modulation of 
intracellular co-enzyme A homeostasis [8]. Acetyl-L-carnitine (ALC), an ester of LC (Figure 1b), 
serves as a source of acetylcholine and L-glutamate, and also contributes to energy-producing reactions. 
Several studies have suggested that LC and ALC may play a neuroprotective role in hypoxic-ischemic 
brain injury [9,10]. The early report demonstrated that LC significantly decreased infarct size 
compared with saline [11], but this result could not be replicated in the subsequent experiments. 
Recent studies have shown that LC pre-treatment ameliorated brain injury after hypoxia-ischemia in 
newborn rats through reducing apoptotic cell death and inhibiting the production of platelet-activating 
factor (PAF) [12]. Others studies have also shown ALC may be of benefit in reducing the infarct size 
and striatal glutamate outflow following focal cerebral ischemia in rats [13]. It is postulated from Int. J. Mol. Sci. 2012, 13 
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references that LC and ALC have different effects on different brain regions as well as different 
treatment methods of them have different effect on neuronal apoptosis. As ALC is an ester of LC, the 
question is which one is better to reduce the brain injury following focal cerebral ischemia? We have not 
seen the comparative study for LC and ALC under the same experimental conditions to clarify its 
neuroprotective effects against ischemic injury. 
This study was therefore designed to determine the effects of LC and ALC administration on brain 
infarct size under the same experimental conditions in vivo and to understand the possible mechanism 
using in vitro model of PC12 cell cultures. 
2. Results 
2.1. ALC, But Not LC, Decreases Infarction Size in SD Rats after MCAO 
To illuminate the protective effects of LC and ALC in acute focal cerebral ischemia, we performed 
MCAO in male SD rats. MCAO model group rats received intraperitoneal injection of PBS only, as 
well as LC and ALC group rats received intraperitoneal injection of LC or ALC (100 mg/kg) 24 h 
prior to MCAO, respectively. Animals were sacrificed 6 h after MCAO or sham surgery for   
2,3,5-triphenyltetrazolium chloride (TTC) staining. A typical TTC staining is shown in Figure 2a. No 
infarction was found in any rats with sham surgery group. ALC (n = 6) pre-treatment obviously 
decreased the infarction size of cortical infarction compared to PBS pretreatment (n = 5) (p ＜ 0.05). 
However, LC pre-treatment had no significant effect on infarct size compared to control group   
(p ＞ 0.05, Figure 2a,b). 
Figure 2. Effects of LC and ALC on infarct size following middle cerebral artery occlusion 
(MCAO) in rats. (a) 2,3,5-triphenyltetrazolium chloride (TTC) staining of cerebral infarct 
size in brain sections from sham groups, MCAO groups, LC (100 mg/kg) and ALC (100 mg/kg) 
pretreated groups at 24 h before MCAO; (b) Quantification of infarct size by TTC staining 
6 h after MCAO. Values are mean ± SEM. * p < 0.05 compared to the MCAO groups,  
n = 6 in each group. 
(a)  (b) 
2.2. LC and ALC Pretreatment Reduces Oxygen-Glucose Deprivation-Induced Cell Injury 
To elucidate the different protective role of LC and ALC on the infarction size in rats after MCAO, 
oxygen-glucose deprivation (OGD)-induced cell injury, a popular neuronal cell injury model in vitro Int. J. Mol. Sci. 2012, 13 
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was used. We firstly detected the effect of OGD on PC12 cells. After the PC12 cells were incubated in 
hypoxic conditions in the absence of glucose for 30, 60, 90, and 120 min, the effects of such conditions 
on the cell viability were determined. The results showed that OGD caused progressive reduction in 
the cell viability time-dependently as determined by thiazolyl blue terazolium bromide (MTT) assay  
(p ＜ 0.05, Figure 3a). After a 120 min exposure to OGD, the cell viability had dropped to ~60%. The 
effects of LC and ALC on the cell viability of non-OGD PC12 cells were also observed. The results 
showed that the cell viability of the non-OGD PC12 cells were not affected by pretreatment with LC 
and ALC (p ＞ 0.05, Figure 3b). However, both LC and ALC pretreatment increased dose-dependently 
the viability of PC12 cells exposed to OGD (p ＜ 0.05, Figure 3c). 
Figure 3. Effects of LC and ALC pretreatment on the viability of PC12 cells exposed to 
oxygen-glucose deprivation (OGD). (a) OGD decreased the viability of PC12 cells   
time-dependently. PC12 cells were treated with OGD for 30, 60, 90, and 120 min, and the 
cell viability was determined by MTT assay (n = 6); (b) Effect of LC and ALC on the 
viability of PC12 cells treated without OGD. Cells were pretreated with 50, 100, 200 or 
400 μmol/L LC and ALC for 24 h, and the cell viability was determined by MTT assay  
(n = 6); (c) Dose-dependent increase of the cell viability by LC and ALC in PC12 cells 
treated with OGD. Cells were pretreated with 50, 100, 200 and 400 μmol/L LC or ALC for 
24 h, followed by OGD exposure for 120 min, and the cell viability was determined by 
MTT assay (n = 6). Values are mean ± SEM. * p < 0.05 compared to the OGD groups. 
(a)  (b) 
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2.3. Pretreatment with LC or ALC Decreases OGD-Induced Cell Apoptosis and Death 
To further illuminate the possible mechanisms responsible for the increase in OGD-induced PC12 
cell viability by LC and ALC pre-treatment, the cell apoptosis and death rate were detected by TUNEL, 
SYTOX, and PI staining, respectively. The positive stained cells were calculated by counting 5 
randomly selected fields, and results were expressed as % positive cells/total cells ± SEM. As shown 
in Figure 4, the percentage of positive TUNEL cells induced by OGD was significantly reduced by LC 
and ALC pre-treatment (p ＜ 0.05), suggesting that LC and ALC inhibit OGD-induced PC12 cell 
apoptosis (Figure 4a). The percentage of positive SYTOX and PI stained cells were calculated as 
above. The results showed that the percentage of positive SYTOX and PI cells induced by OGD was 
significantly reduced by LC and ALC pre-treatment (p ＜ 0.05), suggesting that LC and ALC inhibit 
OGD-induced PC12 cell death (Figure 4b, c). Taken together, LC or ALC pre-treatment increased the 
cell viability by decreasing OGD-induced cell apoptosis and death. 
Figure 4. Effects of LC and ALC pretreatment on apoptosis and necrosis of PC12 cells 
treated with OGD. PC12 cells were pretreated without or with LC (200 µmol/L)) and ALC 
(200 µmol/L) for 24 h before OGD exposure for 120 min. PC12 cells treated without OGD 
used as an normal control. (a) Cell apoptosis were examined by TUNEL fluorescence 
staining; (b) Cell necrosis were examined by SYTOX fluorescence staining; (c) Cell 
necrosis were examined by PI fluorescence staining. * p < 0.05 compared to the OGD 
groups. Original magnifications: 200×. 
 
(a) 
 
(b) Int. J. Mol. Sci. 2012, 13 
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Figure 4. Cont. 
 
(c) 
2.4. Effects of LC or ALC on the SOD, MDA, and ATPase in OGD-Induced PC12 Cells 
Because super oxide dismutase (SOD) is considered as a primary antioxidant defense in cells, we 
observed the SOD activity in the PC12 cells to determine whether LC and ALC had regulatory effects 
on SOD activity after OGD. The results showed that LC or ALC pre-treatment increased the SOD 
activity after OGD (p ＜ 0.05). ATPase, which involves in fluid, electrolyte, and nutrient transport [14], 
was also measured. As shown in Figure 5, the incubation of PC12 cells in OGD conditions could 
decreased obviously the ATPase activity (p ＜ 0.05). When the cells were pretreated with LC or ALC 
for 24 h, the ATPase activity was significantly increased in OGD PC12 cells (p ＜ 0.05). The levels of 
malondialdehyde (MDA), which is a byproduct of a free radical attack on lipids, increased 
significantly after PC12 cells exposure to OGD compared to normal control. LC or ALC pre-treatment 
for 24 h could decrease MDA levels significantly in OGD PC12 cells (p ＜ 0.05). 
Figure 5. Effects of LC and ALC pretreatment on the activity of SOD and ATPase, and the 
level of MDA in PC12 cells exposed to OGD. PC12 cells were pretreated without or with 
LC (200 µmol/L) and ALC (200 µmol/L) for 24 h before OGD exposure for 120 min. 
PC12 cells treated without OGD used as an normal control. (a) Super oxide dismutase 
(SOD) activity in PC12 cells; (b) The levels of MDA in PC12 cells; (c) The ATPase 
activity in PC12 cells. Values given are the mean ± SEM (n = 6). * p < 0.05 compared with  
OGD groups. 
(a)  (b) Int. J. Mol. Sci. 2012, 13 
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Figure 5. Cont. 
(c) 
3. Discussion 
LC and ALC cross the blood-brain barrier and are widely distributed in the central nervous system. 
They have wide roles in brain metabolism [7]. The previous study showed that carnitine has a 
protective effect on hypoxia-ischemia injury [9]. Moreover, carnitine play essential roles in inhibiting 
glutamate-mediated toxicity in vivo via decreasing the affinity of glutamate to its receptor and 
increasing glutamate transport [15,16]. Due to different isomers or modification of the drugs play 
different roles in medical treatment [17], the effects and underlying mechanisms of LC and its acetyl 
ester ALC on the infarction size in rats after MCAO, were tested in the same experimental conditions. 
Clinically, stroke patients need to receive most effective therapy within 6 h. Consequently, in the 
present study, we focused on the effects of LC and ALC pretreatment on the infarct size at 6 h after 
MCAO. We found that pretreatment with ALC, but not LC, decreased the infarction size significantly 
in rats after MCAO, suggesting that ALC was better to reduce the brain injury following focal cerebral 
ischemia. Plasma concentration of free LC is in dynamic balance with ALC and both of them are 
actively transported into cells via the organic cation/carnitine transporter (OCTN) system [18]. It is 
reported that OCTN2 is functionally expressed in rat astrocytes, and is responsible for LC and ALC 
uptake in these cells. The subsequent kinetic analysis showed the Michaelis-Menten constant of LC 
was higher than that of ALC, suggesting that the affinity of LC to its transporter is lower than that of 
ALC [19]. So it is postulated that the different affinity of LC or ALC might play an important role in 
exerting its neuroprotective effects on ischemic injury. A most recent report suggested that ALC 
elevate the glucose uptake and the glucose transporter protein expression level, and the acetyl moiety 
of ALC is metabolized for energy in both astrocytes and GABAergic neurons, which may also 
contribute to its effect of reducing neurotoxicity and neuronal degeneration [20,21]. To elucidate the 
different mechanisms of LC and ALC on the infarction size in rats after MCAO, an in vitro ischemic 
model (oxygen glucose deprivation, OGD) in PC12 cells were used as reported previously [22]. It is 
well known that PC12 cells are the most widely used cellular model for studying neuronal diseases 
including Alzheimer, Parkinson, stroke, and ischemia. In the present study, in vitro ischemia (OGD) 
was delivered by incubating PC12 cells with a medium in which glucose was omitted and oxygen was 
replaced with N2. The viability of PC12 cells decreased progressively when exposed to OGD for 
different times, which indicated that OGD could induce ischemic injury under our experimental Int. J. Mol. Sci. 2012, 13 
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conditions. It is reported that ALC played a role in neuroprotection during hypoxia, which is attributed 
to mitochondrial biosynthesis regulated by ERK1/2-Nrf2 signaling [23]. We found that LC or ALC 
itself did not affect the viability of PC12 cells under normal cultural conditions, but pre-incubation 
with LC or ALC increased the PC12 cell viability when exposed to OGD. Our data suggest that LC 
and ALC both are capable of protecting the PC12 cells from OGD-induced damage in vitro. 
Lately, it is reported that necrotic and apoptotic cell death of many neurons in the ischemic areas 
was found after a stroke event [24]. We hypothesized that LC and ALC would increase the cell 
viability by decreasing OGD-induced cell apoptosis and death. In agreement with this hypothesis, our 
studies  in vitro showed that LC and ALC reduced the cell apoptosis and death rate by TUNEL, 
SYTOX, and PI staining, respectively. It is indicated that the reduction of cell apoptosis and death rate 
by LC or ALC might contribute to its neuroprotective role following in vitro ischemia. 
Oxidative stress has been involved in the pathogenesis of several neurological diseases including 
acute stroke. Dysfunctional mitochondria exposed to oxygen in the penumbral area of the infarct 
generate higher amounts of reactive oxygen species (ROS) than can be scavenged by the antioxidant 
systems, leading to oxidative stress [25]. Ischemic damage is induced by the accelerated formation of 
reactive oxygen species including superoxide and nitric oxide (NO) radicals. These ROS can damage 
cellular components such as proteins, lipids, and DNA, resulting cell apoptosis and death. Recent 
reports demonstrated that LC supplementation has a protective role on exhaustive exercise-induced 
oxidative stress [26]. Previous studies have demonstrated that SOD has a significant role in 
neuroprotection in nature [27], and ALC may lead to SOD stabilization [28]. 
Moreover, as is well known, carnitine prevents free radical formation via inhibiting the activity of 
enzymes involving their generation and via inducting antioxidant mechanisms [29]. Our study showed 
the activity of SOD was significantly decreased in OGD PC12 cells as compared to non-OGD cells, 
and both LC and ALC significantly prevented the decrease of the activity of SOD. The same changes 
did occur in the activity of ATPase. In addition, we also estimated the content of MDA, which is a 
byproduct of a free radical attack on lipids. These results suggested that LC and ALC have the 
neuroprotective effect by improving the state of oxidative stress during ischemic injury. 
Although the exact mechanisms responsible for the inhibition of ischemic injury by ALC in vivo are 
still unclear at this time, at least, our results provide the evidences that LC and ALC pre-treatment are 
highly effective in the prevention against neuronal cell injury in vitro in the same test condition, which 
is consistent with a previous report [30]. Based on our results, we speculated that the different 
pharmacokinetics, mechanism and time of action may result in the different effects of LC and ALC on 
ischemic injury in vivo. Thus, further studies will be required to elucidate the exact mechanisms.  
4. Experimental Section 
4.1. Experimental Animals 
All experimental procedures were approved by the Animal Care and Use Committee of Hebei 
medical University. Male Sprague-Dawley rats weighing 300 ± 30 g were kept under constant 
environmental conditions (temperature, 22 ± 2 °C; humidity, 55 ± 5%; 12-/12-h light/dark cycle) in the 
Animal Research Center of Hebei medical University. Before and after all experimental procedures, all Int. J. Mol. Sci. 2012, 13 
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animals had free access to food and water. Before the experimental procedures, all animals were 
clinically normal and without infection or inflammation, and had no neurological deficits. Rats were 
divided into four groups (sham, MCAO, LC and ALC group). Anesthesia was induced by 4.5% 
halothane in N2O:O2 (70%:30%) and was maintained by inhalation of 1.5% halothane by mask. 
4.2. Transient Middle Cerebral Artery Occlusion (MCAO) 
An intraluminal filament model was used to induce transient MCAO. Briefly, through a midline 
neck incision, the right common, external, and internal carotid arteries were dissected and exposed. 
The common and external carotid arteries were ligated by sutures. A silicone-coated nylon filament 
(diameter: 0.37 mm, Doccal Corporation, Redlands, CA, USA) was then inserted into the external 
carotid artery and gently advanced into the internal carotid artery, until mild resistance was felt, 
indicating that occlusion of the origin of the middle cerebral artery in the Willis circle was achieved. 
The wound was sutured, and the rats were returned to their cages. To understand the protective effects 
of LC and ALC (Sigma, St. Louis, MS, USA) on MCAO model, intraperitoneal injection of LC or 
ALC (100 mg/kg) 24 h before MCAO. MCAO group rats received intraperitoneal injection of PBS only. 
4.3. Measurement of the Infarct Size 
All animals were decapitated 6 h after MCAO. Their brains were quickly removed, placed in cold 
saline solution for 10 min, and then cut into 2-mm-thick coronal slices using a rodent brain matrix. 
Five selected sections were stained in a 2% solution of TTC (Sigma, St. Louis, MS, USA) at 37°C for 
30 min. Areas ipsilateral to the occlusion, which could not be stained, were recorded as infarcted. After 
the sections were fixed with 10% formaldehyde, infarct size was measured by using an imaging system 
(AIS, Imaging Research Inc.), The corrected infarct size was calculated by using an indirect method in 
order to compensate for the effect of brain edema [31]. 
4.4. Cell Culture and Treatments 
Rat pheochromocytoma (PC12) cells (American Type Culture Collection, Rockville, MD, USA) 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% horse serum, 5% fetal bovine serum (FBS), 100 kU/L of penicillin, and   
100 mg/L of streptomycin (Sigma, St. Louis, MS, USA) at 37 °C with a 5% CO2 atmosphere in a 
humidified incubator. All treatments were performed on cells at 60% to 80% confluence. 
4.5. Oxygen-Glucose Deprivation (OGD) 
In order to mimic ischemic-like conditions in vitro, PC12 cells were incubated with glucose-free 
buffer contained 154 mmol/L NaCl, 5.6 mmol/L KCl, 3.6 mmol/L NaHCO3, 2.3 mmol/L CaCl2 and 
5.0 mmol/L HEPES at 37 °C for 15 min in an oxygen-free N2/O2 (95%/5%) atmosphere, and then the 
chamber was sealed and the cells were culture in the hypoxic conditions for 30, 60, 90, and 120 min. 
After incubation for 120 min, cells were removed from the anaerobic chamber to normal culture 
conditions. The cells were divided into control, OGD, OGD plus LC pretreatment and OGD plus ALC 
pretreatment groups. Glucose (1.0 g/L) was added to make glucose containing buffer. The control Int. J. Mol. Sci. 2012, 13 
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group were incubated in glucose containing buffer, and maintained under normoxic conditions. Other 
groups which pretreated with PBS (OGD group), LC (200 µmol/L) or ALC (200 µmol/L) for 24 h, 
respectively, were exposed to OGD for 3 h. 
4.6. Cell Viability Assay 
Cell viability was measured by MTT assay. PC12 cells were seeded at 1 × 10
4 cells/well in 96-well 
plates and allowed to grow in the DMEM medium for 24 h. After LC/ALC and OGD treatment, cells 
were incubated with 5 mg/mL MTT (Sigma, St. Louis, MS, USA) for 4 h, and subsequently solubilized 
in DMSO. The absorbency at 570 nm was then measured using an enzyme-linked immunosorbent 
assay (ELISA) reader. Experiments were repeated at least three times, and the data were expressed as 
the means ± SEM. 
4.7. Measurement of Cell Death and Apoptosis 
The TUNEL method was used to identify the DNA fragmentation of apoptotic cells. The procedure 
was performed following the manufacturer’s instruction (Roche, Basel, Switzerland). Briefly, PC12 
cells were fixed with 4% paraformaldehyde for 30 min and washed with PBS 3 times. Then the cells 
were incubated with 3% H2O2 in 70% methanol for 10 min and washed with PBS twice. After that, the 
cells were incubated with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice. The slides were 
washed with PBS twice and the areas around specimens were dried. Subsequently, TUNEL reaction 
mixture (50 μL) was added to each sample. And then, slides were incubated in a humidified atmosphere 
for 60 min at 37 °C without light. After washing with PBS 3 times, stained sections were analyzed 
with fluorescence microscopy (Olympus, Tokyo, Japan). SYTOX green (Invitrogen, Springfield, OR, 
USA) and propidium iodide (PI, Sigma-Aldrich, St. Louis, MO, USA) were used to stain the cells with 
disrupted membranes (dead cells). Briefly, for SYTOX green staining, SYTOX green (25 nmol/L) was 
added to the PC12 cell cultures. After 10 min at room temperature, specimens were observed with a 
fluorescence microscopy. For PI staining, PC12 cells were incubated in the PI staining solution   
(5 μg/mL in 10 mmol/L PBS) for 10 min at room temperature in the dark. Then, the specimens were 
washed with PBS and mounted on slides. All the specimens were observed with a microscope. Thus, 
this assay includes apoptotic, dead, and viable cells. 
4.8. Measurement of SOD, ATPase Activities and MDA Content 
Neuroprotective effect of LC and ALC was confirmed in terms of excitotoxicity (ATPase activity) 
and oxidative stress (malondialdehyde, MDA; super oxide dismutase, SOD) in the PC12 cells. Briefly, 
total protein was isolated and the protein content was determined with the Bio-Rad Bradford protein 
assay. SOD, ATPase activities and content of MDA assays were performed using the commercial assay 
kits (Jiancheng Institute of Biotechnology, Nanjing, China), following the manufacturer’s protocols.  Int. J. Mol. Sci. 2012, 13 
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4.9. Statistical Analysis 
All data are expressed as mean ± SEM. One-way ANOVA and Duncan’s multiple comparison test 
of the means were done using the software SPSS 16.0 [32] to compare the data obtained. A p-value < 0.05 
was considered statistically significant. 
5. Conclusions 
In this work, we studied the effects of carnitines, LC and ALC, in protecting hypoxia-ischemia 
injury. The principal findings of this study can be summarized as follows: (1) ALC pre-treatment 
decreased the infarct size in the model of MCAO, however, LC pre-treatment had no effect on the 
infarct size in the model of MCAO; (2) both LC and ALC pre-treatment reduced OGD-induced PC12 
cell injury in vitro; (3) both LC and ALC pre-treatment decreased OGD-induced PC12 cell apoptosis 
and death in vitro. These findings suggested that LC and ALC pre-treatment are highly effective in the 
prevention of neuronal cell against ischemic injury in vitro; however, only ALC pre-treatment has a 
protective effect on neuronal cell injury after ischemia in vivo. 
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